Welcome to our dedicated page for VVY news (Ticker: vvy), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Vivoryon Therapeutics has announced significant developments in its kidney disease pipeline. A meta-analysis of VIVIAD and VIVA-MIND studies revealed that varoglutamstat treatment at 600mg twice daily significantly improved kidney function (eGFR) in the overall study population of 286 patients. The improvement became significant after 24 weeks and was maintained for up to 2 years.
The analysis showed a notably larger effect in patients with diabetes compared to those without. Of the total participants, 39 had diabetes (19 on varoglutamstat, 20 on placebo) while 247 were non-diabetic. The company has strengthened its patent portfolio with three new filings, including a composition of matter patent for varoglutamstat's active polymorph.
Vivoryon's key 2025 priority is advancing varoglutamstat in kidney disease through a planned Phase 2b study in diabetic kidney disease (DKD). Additionally, they've nominated a novel QPCT/L inhibitor candidate, VY2149, for development in inflammatory and fibrotic diseases.
Vivoryon Therapeutics reported Q3 2024 results and significant progress with varoglutamstat in kidney disease treatment. Two independent Phase 2 studies (VIVA-MIND and VIVIAD) demonstrated statistically significant improvement in kidney function. The VIVIAD study showed eGFR improvement of 3.4mL/min/1.73m2/year versus placebo, with even stronger results in diabetic patients (8.2mL/min/1.73m2/year).
The company plans to initiate a Phase 2 study in Diabetic Kidney Disease (DKD), pending additional funding or partnership. Financial results show R&D expenses increased to EUR 12.6 million, while G&A expenses decreased to EUR 4.9 million. Cash position stands at EUR 12.5 million as of September 30, 2024, with runway extended into Q3 2025.
Vivoryon Therapeutics announced topline Phase 2 data from the VIVA-MIND study of varoglutamstat in early Alzheimer's disease. The study showed a statistically significant improvement in kidney function, with patients treated with varoglutamstat 600mg BID showing an average improvement of >4mL/min/1.73m2 in estimated glomerular filtration rate (eGFR) versus placebo (p<0.001).
However, the study did not meet its primary and key secondary endpoints for Alzheimer's disease treatment, aligning with previous VIVIAD study results. The drug maintained a favorable safety profile with no new safety signals detected across over 400 participants in Phase 1 and 2 studies. The company plans to advance into a Phase 2 study in diabetic kidney disease, subject to additional funding/partnership.
Vivoryon Therapeutics, a clinical stage company focused on developing small molecule medicines for modulating pathologically altered proteins, has announced it will release its Q3 2024 financial results and provide a corporate update on December 10, 2024.
The company will host a conference call and webcast at 3:00 pm CET / 9:00 am ET. The event will be accessible via phone through pre-registration and through a live audio webcast on Vivoryon's website. Participants are advised to join 15 minutes before the scheduled start time.
Vivoryon Therapeutics presented Phase 2b results for varoglutamstat at ASN Kidney Week 2024, showing significant kidney function improvements. The study demonstrated a 3.4mL/min/year improvement in eGFR compared to placebo (p<0.0001), with an even more substantial 8.2mL/min/year improvement in diabetic patients (p=0.02). The drug showed excellent safety and tolerability with no increased proteinuria. Based on these results, Vivoryon is planning a new Phase 2 study focusing on patients with Diabetic Kidney Disease (DKD) stages 3b and 4. The company also sees potential applications in rare kidney diseases like Fabry disease and Alport syndrome.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) announced that its abstract on Varoglutamstat has been selected for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, California, from October 23 to 27. The abstract titled 'Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)' will be presented by Frank Weber, M.D., CEO, on October 25, 2024, at 5:40 PM PDT.
Varoglutamstat (PQ912) is a potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL, with potential therapeutic applications in inflammatory and fibrotic diseases, neurodegenerative diseases, and cancer. Initially developed for Alzheimer's disease (AD), it has shown favorable safety and tolerability in various clinical studies. The Phase 2 VIVIAD study in AD included the investigation of kidney function to explore the role of QPCT/L inhibition on kidney function.
Vivoryon Therapeutics N.V. (VVY) hosted a virtual Kidney Disease Key Opinion Leader (KOL) Event on September 30, 2024, focusing on diabetic kidney disease (DKD) and the potential of their lead asset, varoglutamstat. Key takeaways include:
1. Chronic Kidney Disease (CKD) is a rising global health problem, with diabetes being a major risk factor.
2. Current treatments do not halt or reverse kidney function decline, highlighting a significant unmet need.
3. Varoglutamstat's novel mode of action targeting inflammatory and fibrotic pathways shows promise in addressing this need.
4. Analysis of the VIVIAD Phase 2b study data revealed a substantial treatment effect on eGFR slope, particularly in patients with type 2 diabetes.
5. The company plans to advance varoglutamstat into a Phase 2 study in DKD, currently in the planning stage.
Vivoryon Therapeutics reported significant advancements in H1 2024, particularly with varoglutamstat, a Phase 2 drug showing notable improvements in kidney function for patients with kidney disease. The VIVIAD Phase 2b study highlighted a statistically significant benefit in eGFR and reduced pro-inflammatory cytokine pE-CCL2 levels. A significant benefit was also noted in diabetic subgroups, leading to plans for a Phase 2 study in diabetic kidney disease (DKD).
The company shifted focus to inflammatory and fibrotic diseases due to these results. Financially, Vivoryon reported a net loss of €13.6M for H1 2024 and a decrease in cash and equivalents to €15.3M.
Key upcoming events include a conference call and a virtual Kidney Disease KOL webcast to discuss the drug's potential further. The company is also seeking business development and financing opportunities to support its initiatives.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) has completed a share capital reduction by decreasing the nominal value of its shares from €1.00 to €0.01. This change, approved by shareholders at the 2024 AGM, aims to:
- Improve the company's ability to attract new financing
- Pursue M&A activities
- Enhance incentives for management and employees through equity awards
- Improve the company's equity composition
The number of ordinary shares remains unchanged at 26,066,809. The €0.99 per share reduction has been added to the company's distributable reserves. Updated articles of association are now available on Vivoryon's website.
Vivoryon Therapeutics N.V. (VVY), a clinical stage company developing small molecule medicines for pathologically altered proteins, has announced two upcoming events in September 2024:
1. Half Year 2024 Results on September 12, 2024, at 3:00 pm CEST / 9:00 am EDT. The company will publish financial results and provide a corporate update. A conference call and webcast will be available to the public.
2. Virtual Kidney Disease KOL Event on September 30, 2024, at 3:00 pm CEST / 9:00 am EDT. Further details and participation information will be provided on the company's website.
Both events will be accessible via webcast on Vivoryon's website. For the half-year results call, participants can pre-register for dial-in details.